SMAD6: A Potential Drug Target for Cancer (G4091)

Target Name: SMAD6

NCBI ID: G4091

SMAD6

SMAD6: A Potential Drug Target for Cancer

SMAD6 is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and gastrointestinal tract. It is a member of the SMAD family of proteins, which are involved in the regulation of gene expression and DNA replication. SMAD6 has has been shown to play a role in the development and progression of several diseases, including cancer. As a result, SMAD6 has potential as a drug target or biomarker.

SMAD6 was first identified in the 1990s as a tumor suppressor protein that is expressed in several tissues during the development and progression of cancer. Since then, several studies have demonstrated that SMAD6 plays a critical role in the regulation of cell growth, apoptosis, and inflammation.

SMAD6 functions as a negative regulator of the negative transcription factor RNA polymerase (RNA polymerase), which is responsible for transcribing DNA into RNA. In cancer cells, RNA polymerase is often overexpressed, leading to the production of abnormal amounts of RNA and the formation of abnormal RNA-protein hybrids. These aberrations can disrupt the normal regulation of gene expression and contribute to the development and progression of cancer.

SMAD6 has been shown to regulate the activity of RNA polymerase in a variety of ways. One of its most well-studied functions is its ability to inhibit the polymerase's ability to bind to specific DNA sequences. This interaction between SMAD6 and RNA polymerase is critical for the regulation of gene expression and the development of cancer.

In addition to its role in regulating RNA polymerase, SMAD6 has also been shown to play a role in the regulation of cellular signaling pathways. It is a negative regulator of the TGF-β pathway, which is involved in the regulation of cell growth, differentiation , and inflammation. The TGF-β pathway is often overexpressed in cancer, leading to the development and progression of cancer.

SMAD6 has also been shown to play a role in the regulation of cellular apoptosis, which is the process by which cells undergo programmed cell death. During apoptosis, SMAD6 is involved in the formation of apoptotic structures, such as caspases and tightly-packed chromatin, which are thought to contribute to the disruptive regulation of gene expression that occurs during this process.

SMAD6 has also been shown to play a role in the regulation of inflammation, which is a critical aspect of cancer progression. It is a negative regulator of the NF-kappa-B pathway, which is involved in the regulation of inflammation and immune responses. The NF -kappa-B pathway is often overexpressed in cancer, leading to the development and progression of cancer.

In conclusion, SMAD6 is a protein that has been shown to play a critical role in the regulation of gene expression and the development and progression of cancer. As a result, SMAD6 has potential as a drug target or biomarker. Further research is needed to fully understand the role of SMAD6 in cancer development and to develop effective treatments.

Protein Name: SMAD Family Member 6

Functions: Transforming growth factor-beta superfamily receptors signaling occurs through the Smad family of intracellular mediators. SMAD6 is an inhibitory Smad (i-Smad) that negatively regulates signaling downstream of type I transforming growth factor-beta (PubMed:9436979, PubMed:16951688, PubMed:22275001, PubMed:9759503, PubMed:10647776, PubMed:10708948, PubMed:10708949, PubMed:30848080). Acts as a mediator of TGF-beta and BMP anti-inflammatory activities. Suppresses IL1R-TLR signaling through its direct interaction with PEL1, preventing NF-kappa-B activation, nuclear transport and NF-kappa-B-mediated expression of pro-inflammatory genes (PubMed:16951688). Blocks the BMP-SMAD1 signaling pathway by competing with SMAD4 for receptor-activated SMAD1-binding (PubMed:9436979, PubMed:30848080). Binds to regulatory elements in target promoter regions (PubMed:16491121)

The "SMAD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets